MAP2K1 and neoplasm: The MAP2K1 mutation yielding a p.Cys121Ser coding shift was the most common in the combined HCLv/HCLc-IGHV4-34 tumour panel, and MAP2K1 mutations associated with predicted constitutive enzymatic activity [13].